Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
02 août 2022 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, August 3, 2022,...
Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
03 mai 2022 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) net revenue of $22.2 million in Q1 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Cash reserves expected to fund operations into at...
Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022
02 mai 2022 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30...
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
22 févr. 2022 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 –– ARCALYST collaboration achieved profitability in Q4 2021 –– ARCALYST full-year 2022 net revenue expected...
Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
22 févr. 2022 07h59 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Collaboration includes rights to develop and commercialize ARCALYST® and mavrilimumab in the Asia Pacific Region (excluding Japan) – – Kiniksa to receive $22 million upfront; eligible to receive...
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
18 févr. 2022 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 22, 2022,...
Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones
10 janv. 2022 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
- ARCALYST® full-year 2022 guidance to be provided with Q4 2021 financial results -- Vixarelimab Phase 2b data in prurigo nodularis expected in 2H 2022 –- KPL-404 Phase 2 trial in rheumatoid arthritis...
Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
03 janv. 2022 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday,...
Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS
28 déc. 2021 06h59 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate...
Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference
23 nov. 2021 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 4th Annual...